Becton, Dickinson Boosts FY23 Outlook - Update

RTTNews | 631 days ago
Stocktwits
Becton, Dickinson Boosts FY23 Outlook - Update

(RTTNews) - While reporting financial results for the second quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings and revenue outlook for fiscal 2023.

For fiscal 2023, the company now projects adjusted earnings in a range of $12.10 to $12.32 per share on revenues between approximately $19.2 billion to $19.3 billion, with currency-neutral revenue growth of 6.5 to 7.0 percent.

Previously, the company expected adjusted earnings in a range of $12.07 to $12.32 per share on revenues between approximately $19.1 billion to $19.3 billion, with currency-neutral revenue growth of 5.75 to 6.75 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $12.21 per share on revenue growth of 1.9 percent to $19.22 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Tags: BDX
Stocktwits
read more
Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update

Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update

While reporting financial results for the third quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings guidance for fiscal 2024, while trimming annual revenue outlook.
RTTNews | 176 days ago
BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters

BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters

Medical technology company BD or Becton, Dickinson and Co. (BDX) announced Friday the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.
RTTNews | 294 days ago
BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device

BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device

Medical technology company Becton, Dickinson and Co. or BD (BDX) announced Thursday it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
RTTNews | 414 days ago
Becton, Dickinson Boosts FY23 Outlook - Update

Becton, Dickinson Boosts FY23 Outlook - Update

While reporting financial results for the first quarter on Thursday, medical technology company Becton, Dickinson and Co. or BD (BDX) raised its adjusted earnings and revenue outlook for fiscal 2023.
RTTNews | 722 days ago
Swiss Market Ends Marginally Up

Swiss Market Ends Marginally Up

The Switzerland market closed marginally up on Friday after staying in a tight band above the flat line right through the day's trading session. Investors continued to assess recent economic data and U.S. President Donald Trump's remarks about potential new tariffs and call for interest rate cuts.
RTTNews | 5h 44min ago
European Stocks Fail To Hold Early Gains, Close Flat

European Stocks Fail To Hold Early Gains, Close Flat

European stocks closed on a mixed note on Friday, taking a breather of sorts, after recent strong gains amid optimism about further monetary easing by global central banks. Worries about tariff threats eased a bit, but not fully, and investors largely chose to refrain from making significant moves.
RTTNews | 6h 1min ago
Tools
Economic Calendar
Market Hours
Interest Rates
Holidays Calendar
Forex Market
Forex Volatility
Forex Correlation
Forex News
forex analysis
COT Data
Liquidity
Forex Calculators
Forex Heat Map
Indicators Heatmap
Community
Community
Systems
Most Popular Systems
Strategies
Contests
Forex Charts
Forex Sentiment
Sentiment Indicator
Reviews
Brokers
Prop Trading Firms
VPS Services
Signal Providers
EA Programming Services
Affiliate Programs
PAMM Broker Services
Rebate Program Services
Trading Platforms
Expert Advisors
Crypto Exchanges
Trading Courses
Brokers
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions Broker News
Platform
Widgets
Features
API
RSS
Stock Portfolio
Affiliate Software
Advanced Charts
Support
FAQ
Help
Contact Us
Report a Bug!
About
Blog
© 2025 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.